TY - JOUR
T1 - The personal touch
T2 - Strategies toward personalized vaccines and predicting immune responses to them
AU - Kennedy, Richard B.
AU - Ovsyannikova, Inna G.
AU - Lambert, Nathaniel D.
AU - Haralambieva, Iana H.
AU - Poland, Gregory A.
N1 - Funding Information:
All authors have NIH-funded grants/contracts to study the immunogenetics of viral vaccine responses and systems biology approaches to understanding influenza vaccines. The authors acknowledge support from NIH grants U01AI089859, R37AI48793, and R01AI33144, and from the National Institute of Allergies and Infectious Diseases, NIH, Department of Health and Human Services, under contract number HHSN266200400065C (N01AI40065). Dr Poland is the chair of a Safety Evaluation Committee for novel nonrubella investigational vaccine trials being conducted by Merck Research Laboratories. Dr Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics, PAXVAX Inc and Emergent Biosolutions. Drs Poland and Ovsyannikova hold patents related to vaccinia and measles peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. Mayo Clinic research reported here has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies and the Mayo Clinic IRB or IACUC as appropriate. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
PY - 2014/5
Y1 - 2014/5
N2 - The impact of vaccines on public health and wellbeing has been profound. Smallpox has been eradicated, polio is nearing eradication, and multiple diseases have been eliminated from certain areas of the world. Unfortunately, we now face diseases such as hepatitis C, malaria or tuberculosis, as well as new and re-emerging pathogens for which we lack effective vaccines. Empirical approaches to vaccine development have been successful in the past, but may not be up to the current infectious disease challenges facing us. New, directed approaches to vaccine design, development, and testing need to be developed. Ideally these approaches will capitalize on cutting-edge technologies, advanced analytical and modeling strategies, and up-to-date knowledge of both pathogen and host. These approaches will pay particular attention to the causes of inter-individual variation in vaccine response in order to develop new vaccines tailored to the unique needs of individuals and communities within the population.
AB - The impact of vaccines on public health and wellbeing has been profound. Smallpox has been eradicated, polio is nearing eradication, and multiple diseases have been eliminated from certain areas of the world. Unfortunately, we now face diseases such as hepatitis C, malaria or tuberculosis, as well as new and re-emerging pathogens for which we lack effective vaccines. Empirical approaches to vaccine development have been successful in the past, but may not be up to the current infectious disease challenges facing us. New, directed approaches to vaccine design, development, and testing need to be developed. Ideally these approaches will capitalize on cutting-edge technologies, advanced analytical and modeling strategies, and up-to-date knowledge of both pathogen and host. These approaches will pay particular attention to the causes of inter-individual variation in vaccine response in order to develop new vaccines tailored to the unique needs of individuals and communities within the population.
KW - immunogenetics
KW - microbiome
KW - personalized vaccinology
KW - systems biology
KW - systems vaccinology
KW - vaccines
KW - vaccinomics
UR - http://www.scopus.com/inward/record.url?scp=84908141427&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908141427&partnerID=8YFLogxK
U2 - 10.1586/14760584.2014.905744
DO - 10.1586/14760584.2014.905744
M3 - Review article
C2 - 24702429
AN - SCOPUS:84908141427
SN - 1476-0584
VL - 13
SP - 657
EP - 669
JO - Expert review of vaccines
JF - Expert review of vaccines
IS - 5
ER -